Effectively managing sulphur burps whilst continuing GLP-1 therapy requires a multifaceted approach focusing on dietary modifications, eating habits, and lifestyle adjustments
A clinical trial evaluating the effects of exenatide in patients with T2DM over a period of 3 years revealed that treatment lead to significant improvements in hepatic markers, such as elevated liver enzymes, and other cardiovascular risk factors were significantly improved [34]
Byetta is taken twice daily, while Bydureon is a once-weekly extended-release injection
Both medications are processed through different liver enzymes and excretion routes, making them compatible from a pharmacological standpoint
The result is reduced caloric intake without the willpower battle that makes conventional dieting fail for most people
Two therapeutic approaches in particular are drawing increasing attention, not as standalone symptom managers but as potential tools for addressing the deeper biology of this transition